Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Bioorganic & Medicinal Chemistry Letters|March 20, 2009
Anthranilamide-based N,N-dialkylbenzamidines as potent and orally bioavailable factor Xa inhibitors: P4 SARPenglie Zhang, Liang Bao, Jingmei Fan, et al.
RNA (New York, N.Y.)|May 21, 2025
Evaluation of novel computational methods to identify RNA-binding protein footprints from structural dataOrel Mizrahi, Meredith Corley, Ori Feldman, et al.
Bioorganic & Medicinal Chemistry Letters|March 18, 2003
Design, synthesis, and structure-activity relationships of unsubstituted piperazinone-based transition state factor Xa inhibitorsWenrong Huang, Mary Ann Naughton, Hua Yang, et al.
Plos One|February 9, 2017
Identification of a vacuolar proton channel that triggers the bioluminescent flash in dinoflagellatesJuan D Rodriguez, Saddef Haq, Tsvetan Bachvaroff, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|May 17, 2003
Inhibition of purified factor Xa amidolytic activity may not be predictive of inhibition of in vivo thrombosis: implications for identification of therapeutically active inhibitorsUma Sinha, Pei Hua Lin, Susan T Edwards, et al.
Oncotarget|July 6, 2015
Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycyclineMary Pulvino, Luojing Chen, David Oleksyn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 3, 2026
Outcomes associated with empiric azithromycin use among patients hospitalized with non-severe community-acquired pneumonia: emulation of a target trialAshwin B Gupta, Emily Walzl, David Ratz, et al.
Bioorganic & Medicinal Chemistry Letters|July 1, 2004
Parallel synthesis and structure-activity relationships of a series of highly potent, selective, and neutral factor Xa inhibitorsShawn M Bauer, Erick A Goldman, Wenrong Huang, et al.
BMJ (Clinical Research Ed.)|August 16, 2006
Developing a quality criteria framework for patient decision aids: online international Delphi consensus processGlyn Elwyn, Annette O'Connor, Dawn Stacey, et al.
Bioorganic & Medicinal Chemistry Letters|March 20, 2009
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitorPenglie Zhang, Wenrong Huang, Lingyan Wang, et al.
Pageof 5